Thymalfasin

A thymus hormone polypeptide found in thymosin fraction 5 (a crude thymus gland extract) but now produced by synthesis. It is used alone or with interferon as an immunomodulator for the treatment of CHRONIC HEPATITIS B and HEPATITIS C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression, and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients.

Also Known As:

Networked: 236 relevant articles (36 outcomes, 54 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Garaci, Enrico: 12 articles (01/2021 - 08/2003)
2.	Romani, Luigina: 7 articles (01/2021 - 10/2006)
3.	Matteucci, Claudia: 6 articles (01/2021 - 08/2003)
4.	Mastino, Antonio: 5 articles (01/2021 - 08/2003)
5.	Rasi, Guido: 5 articles (11/2007 - 08/2003)
6.	Balestrieri, Emanuela: 4 articles (01/2021 - 10/2012)
7.	Pica, Francesca: 4 articles (01/2018 - 08/2003)
8.	Tuthill, Cynthia: 4 articles (01/2015 - 05/2002)
9.	Bonifazi, Pierluigi: 4 articles (04/2010 - 10/2006)
10.	Bozza, Silvia: 4 articles (04/2010 - 10/2006)

Related Diseases

1.	Chronic Hepatitis B 05/01/1998 - "Thymosin alpha1 (Talpha) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. " 10/01/2003 - "The efficacy of thymosin alpha 1 (Talpha1) in patients with chronic hepatitis B still requires confirmation. " 05/01/1998 - "Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial." 09/01/1999 - "Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study." 11/01/2010 - "[In vitro effect of thymosin alpha 1 on the function of dendritic cells derived from chronic hepatitis B patients]."
2.	Neoplasms (Cancer) 01/01/2015 - "Combination of thymalfasin significantly improved survival and prolonged the time to tumor recurrence in patients who received transcatheter arterial chemoembolization after tumor resection. " 01/01/2003 - "Treatment of thymosin alpha 1 increased the number of CD4 cells and improved the NK activity, and also improved the quality of life of the elderly patients with malignant tumor. " 05/01/1985 - "Thymosin alpha 1, in vitro, was associated with improvement in LMI in the cancer patients. " 01/01/1999 - "Thymosin alpha1 kinetics from this study are comparable to those previously obtained in Japanese volunteers or cancer patients, but may be influenced by the drug formulation used." 10/01/2015 - "Thymosin alpha 1 (Tα1) is commonly used for treating several diseases; however its usage has been limited because of poor penetration of the target tissue, such as tumor cells. "
3.	Sepsis (Septicemia) 01/17/2013 - "The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial." 01/01/2009 - "[Evaluation of efficacy of thymosin alpha1 in the treatment of sepsis: a systematic review]." 01/01/2018 - "Thymosin alpha 1 (Tα1), acting as an immune modulator, exerts great biological influence in activating and restoring the dysregulated immune response for patients with sepsis. " 01/01/2018 - "Thymosin alpha 1 treatment for patients with sepsis." 01/17/2013 - "In light of the crucial role of immunologic derangement in severe sepsis, thymosin alpha 1 (Tα1) is considered as a promising beneficial immunomodulatory drug. "
4.	Infections 01/01/2017 - "This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. " 10/01/2008 - "Thymalfasin has shown efficacy in the treatment of chronic HCV infection. " 05/01/2002 - "SciClone developed and launched Talpha1, under the trade name Zadaxin, for the treatment of HBV and hepatitis C virus (HCV) infections. " 07/01/1989 - "Since thymosin alpha 1 has been shown to increase T-cell mediated immunity, and to enhance host resistance to infection, it may play an important role in the maturation of mucosal immunity and host resistance in general in the neonate. " 01/01/1985 - "The data are discussed with regard to the immunomodulating capacity of thymosin alpha 1 and to our previously reported observations concerning the ability of the drug to modulate the resistance against systemic Candida albicans infection."
5.	Chronic Hepatitis C 06/01/1996 - "A randomized, double-blind, placebo-controlled trial was performed to evaluate the efficacy and safety of thymosin alpha 1 (alpha 1) in treating chronic hepatitis C. " 06/01/1996 - "A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C." 11/01/1996 - "To assess the response in patients with chronic hepatitis C to one year of combination treatment: thymosin alpha 1 (T alpha 1), 1 mg twice weekly, and lymphoblastoid (L)-IFN, 3 MU thrice weekly. " 06/01/1996 - "No side effects were reported except for local discomfort at the injection sites, reported by some patients treated with thymosin alpha 1. In conclusion, this regimen of thymosin alpha 1 is not effective in the treatment of chronic hepatitis C." 06/01/2001 - "The efficacy and safety of IFN alpha 2a and Thymosin alpha1 combination therapy in patients with chronic hepatitis C were determined. "

Related Drugs and Biologics

1.	Interferon-alpha (Interferon Alfa)
2.	Interferons
3.	urinastatin (MR 20)
4.	Peptides (Polypeptides)
5.	Ribavirin (Virazole)
6.	Thymalfasin
7.	thymosin fraction 5
8.	Interleukin-2 (IL2)
9.	Cyclophosphamide (Cytoxan)
10.	Amantadine (Aman)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunomodulation
3.	Immunotherapy
4.	Drug Therapy (Chemotherapy)
5.	Hematopoietic Stem Cell Transplantation